Health Care·Biotechnology·$29.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | +4.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | +4.09% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management conveyed a cautious outlook, acknowledging the difficulties faced in the current market environment. They reiterated their commitment to long-term objectives.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategic goals despite current setbacks.
Insmed Inc's earnings report showed a narrower-than-expected loss per share, which was a slight positive surprise. However, the lack of revenue data and no guidance contributed to a negative stock reaction, with shares falling 0.81%. Investors may be concerned about the company's future performance given the current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016